Form 4 for KROS Keros Therapeutics, Inc.
Accepted 2022-06-14 00:00:00 ET · period of report 2022-06-14 · accession 0001209191-22-036800 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-06-14 | 2022-06-14 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.3 | +9,400 | 95.1K | +11% | +$2,820 |
| D | 2022-06-14 | 2022-06-14 | KROS | Lachey Jennifer | CSO | M - OptEx | $0.00 | -9,400 | 56.7K | -14% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-06-14 | M | A | 9,400 | $0.3 | 95,100 | D | — | — | |
| 2 | Derivative | Employee Stock Option (right to buy) | 2022-06-14 | M | D | 9,400 | $0.00 | 56,705 | D | $0.3 · — to 2028-03-25 | 9,400 Common Stock | (F1) Immediately exercisable. |